RARainier Arnolda

Rainier Arnolda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rainier Arnolda has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Estimating the Healthcare Cost of Infection-Related Hospitalisations in Multiple Myeloma

    by Rainier Arnolda, Sara Carrillo de Albornoz, Laura Fanning, Adam Irving, Aleece MacPhail, Erica Wood, Zoe McQuilten, Andrew Spencer, Dennis Petrie

  • Open Access

    Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study

    by Rachel Delahunty, Madawa Jayawardana, Rainier Arnolda, Thuan Tzen Koh, Michael S Hofman, Kym Reid, Julie Lamont, Caitlyn Nguyen-Ngo, Hayley M Johnston, Nicole G Brooks, et al.


  • Open Access

    Cost of Serious Infections in Chronic Lymphocytic Leukemia

    by Sara Carrillo de Albornoz, Rainier Arnolda, Alisa M. Higgins, Erica M. Wood, Zoe K. McQuilten, Dennis Petrie

    Background: The economic burden of chronic lymphocytic leukemia (CLL) is high, and is projected to increase with the introduction of new targeted treatments and improved survival. These high costs are not only associated with anticancer treatment, but also with the treatment and prevention of CLL symptoms and adverse events. Infections are among the most common adverse events in CLL patients, resulting from immune dysregulation caused by both the underlying disease and treatments. Immunoglobulin replacement therapy (IgRT) is one prophylactic measure used to prevent infections, but its effectiveness in CLL is unclear and costs are substantial. The aim of this paper was to estimate the excess cost associated with serious infections in patients with CLL, and explore other factors that may increase hospitalization costs in Australia. Methods: We conducted a retrospective longitudinal study of linked hospital data, including 3705 patients with CLL and hospital admissions between July 2016 and June 2022. We estimated the excess cost associated with serious infections, inhospital anticancer treatment and IgRT using generalized linear models with gamma distribution and identity link. Results: Over the study period, the mean inhospital cost per patient per month was AU$1291 (US$892) and was highest in the month of CLL diagnosis, at AU$4168 (US$2880). The excess cost in the month of a serious infection was AU$22,905 (US$15,829) per patient, and costs remained higher in the subsequent 6 months. The monthly costs associated with IgRT and anticancer treatment were AU$3288 (US$2772) and AU$5223 (US$3609) per patient, respectively. Conclusion: Our results highlight the high economic burden of serious infections in a large cohort of patients with CLL over a 6‐year period. Further costing studies including costs to the patient and healthcare utilization in the outpatient setting are needed to ascertain the total cost of infections and the overall cost of cancer care in patients with CLL.

  • Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials

    by Cloud P. Paweletz, Thomas D. Forbes, Laura Yee, Grace Heavey, Hua-Jun He, Zhiyong He, Dana Connors, Daniel Stetson, Susan Keating, Kenneth D. Cole, et al.

    PURPOSE: We previously developed quality control materials (QCMs) to aid in the development of circulating tumor DNA (ctDNA) assays. In this study, we further characterize the performance of the QCMs relative to clinical samples. METHODS: QCMs were provided by three manufacturers. To functionally characterize the QCMs, we (1) evaluated EGFR L858R and ex19del (range, 0.5%-5.0% variant allele frequency [VAF]) in QCMs compared with clinical samples by droplet digital polymerase chain reaction (ddPCR), targeted-amplicon sequencing (Tag-seq), and hybrid capture next-generation sequencing (NGS); and (2) evaluated the QCMs and clinical samples near the Tag-seq limit of detection. A clinical pilot was also conducted in 11 clinical laboratories spanning four continents. RESULTS: For functional characterization, part 1, QCM VAFs for hybrid capture were similar to ddPCR for EGFR L858R but lower for ex19del. By contrast, hybrid capture results for EGFR L858R clinical samples showed a positive trend compared with ddPCR. For amplicon NGS, QCMs performed similarly to clinical samples for both variants. For part 2, observed hit rates approximated expected values. In the clinical pilot, median ex19del VAF was higher for Tag-seq than hybrid capture for both 1.0% and 0.5% QCM formulations. Median QCM L858R VAFs were similar for Tag-seq and hybrid capture, with greatest interlaboratory differences observed for Thermo Fisher Scientific QCMs. For non- EGFR variants, we observed assay and QCM-dependent trends, with no particular QCM or assay driving these trends. CONCLUSION: This project revealed unexpected differences in performance of both assays and QCMs. These findings highlight the need for further validation across diverse alteration types and merit consideration by laboratories that rely on QCMs to develop and perform ctDNA assays for diagnostic applications.

  • Open Access

    Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia

    by Sara Carrillo de Albornoz, Xin Zhang, Rainier Arnolda, Aleece MacPhail, Adam Irving, Alisa M. Higgins, Erica M. Wood, Zoe K. McQuilten, Dennis Petrie

    Patients with chronic lymphocytic leukemia (CLL) often experience infections due to immune suppression and/or dysregulation. Hypogammaglobulinemia is a key contributor to immunosuppression in CLL, and immunoglobulin replacement therapy (IgRT) is commonly given to prevent infections. However, the benefit of IgRT in preventing serious infections in CLL remains unclear. This study aimed to describe IgRT treatment patterns in a large, real-world cohort of patients with CLL, and explore the association between IgRT and serious infections. We conducted a retrospective longitudinal study of linked hospital data, including 6217 patients with CLL between 2008 and 2022 in Victoria, Australia. Kaplan-Meier survival analyses were performed to estimate survival, infection incidence, and IgRT use. Cox survival analyses explored associations between infections and IgRT in patients receiving regular prophylactic IgRT. Over the 14-year follow-up, the monthly proportion of patients experiencing serious infections doubled, while the proportion of patients receiving any IgRT quadrupled. The median time to death from CLL diagnosis was 10 years, and patients with serious infections had a higher mortality rate (0.090 [95% confidence interval (CI), 0.074-0.110]) vs those without (0.008 [95% CI, 0.007-0.009]). In total, 753 patients (12.1%) received IgRT, and 524 (8.4%) received IgRT regularly. In patients who received regular IgRT, infection incidence was higher during periods of IgRT (0.056 [95% CI, 0.052-0.060]) compared with periods without IgRT (0.038 [95% CI, 0.035-0.042]). Serious infections were associated with not only IgRT initiation and reinitiation, but also cessation. Further research is needed to evaluate the causal relationship between IgRT and infections in this population.


  • Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA

    by Rainier Arnolda, Kerryn Howlett, Timmy Chan, Jeanette Raleigh, Athena Hatzimihalis, Anthony Bell, Andrew Fellowes, Shahneen Sandhu, Grant A. McArthur, Stephen B. Fox, et al.